Novo Nordisk (NVO) the newly approved version of Wegovy is scheduled to arrive directly to US self-checkout channels in early January, Reuters’ Maggie Fick reports. As part of the company’s agreement with the Trump administration in November, Novo and Lilly (LYLY) agreed to sell initial doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients, as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.
First published in the fly – the definitive source of breaking financial news that moves the market in real time. Try it now >>
See the top stocks recommended by analysts >>
Read more about NVO:
Disclaimer and disclosure Report a problem